Document is current

Article History

Received: 19 October 2019

Accepted: 15 June 2020

First Online: 20 June 2020

Compliance with ethical standards

:

: Dr. Oizumi reports personal fees from Eli Lilly K.K., during the conduct of the study; grants and personal fees from AstraZeneca K.K., grants and personal fees from Bristol-Myers Squibb K.K., grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants from Kyowa Hakko Kirin Co., Ltd. (currently Kyowa Kirin Co., Ltd.), grants and personal fees from Ono Pharmaceutical Co., Ltd., grants from Merck Serono Co., Ltd. (currently Merck Biopharma Co., Ltd.), personal fees from MSD K.K., and grants and personal fees from Taiho Pharmaceutical Co., Ltd., outside the submitted work. Dr. Fujita reports personal fees from Taiho Pharmaceutical Co., Ltd., personal fees from Eli Lilly K.K., personal fees from Chugai Pharma Co., Ltd., and personal fees from AstraZeneca K.K., outside the submitted work. Dr. Toshiyuki Harada reports personal fees from Boehringer Ingelheim GmbH, personal fees from Hisamitsu Pharmaceutical Co. Inc., personal fees from GlaxoSmithKline K.K., outside the submitted work. Dr. Kinoshita reports personal fees from Novartis Pharma K.K., personal fees from Chugai Pharmaceutical Co., Ltd., and personal fees from Pfizer Inc., outside the submitted work. The remaining authors declare no conflict of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (include name of committee + reference number) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.